Nalaganje...
ACS Chemical Neuroscience Molecule Spotlight on Saredutant
[Image: see text] Saredutant (SR48968), a potentially novel treatment option for major depressive disorders (MDD) and generalized anxiety disorder (GAD), is a drug from Sanofi-Aventis currently in phase III clinical trials. MDD is a common mental disorder that affects 121 million people worldwide, n...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Chemical Society
2010
|
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3368631/ https://ncbi.nlm.nih.gov/pubmed/22776916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/cn100061r |
| Oznake: |
Označite
Brez oznak, prvi označite!
|